Navigation Links
Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
Date:3/27/2008

CINCINNATI, March 27 /PRNewswire/ -- Ethicon Endo-Surgery announced today that the company has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the SEDASYS(TM) System, the first computer-assisted personalized sedation (CAPS) system.

The SEDASYS(TM) System is intended for use by physician/nurse teams to administer minimal to moderate propofol sedation to patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy), and disorders of the upper gastrointestinal tract (EGD). For routine colonoscopy or EDG procedures, physicians prefer the sedative propofol (also known as DIPRIVAN(R)), which produces rapid onset and quick recovery for patients(i).

The PMA submission includes results from a multi-center prospective, randomized, controlled trial of 1,000 patients that compared the safety and effectiveness of the SEDASYS(TM) System to the current standard of care for sedation in routine endoscopic procedures - physician-administered benzodiazepine and opioids. The pivotal clinical trial was conducted from March 2007 to October 2007 at eight locations in the U.S.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at http://www.ethiconendo.com.

SEDASYS is a trademark of Ethicon Endo-Surgery

DIPRIVAN(R) is a registered trademark of the AstraZeneca group of companies.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward- looking statements as a result of new information or future events or developments.)

(i) American Gastroenterological Association press release March 8, 2004. "Gastroenterological Societies Reach Consensus on Recommendations for Sedation During Endoscopic Procedures"


'/>"/>
SOURCE Ethicon Endo-Surgery
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
2. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
3. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
7. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. Takeda submits new drug application for alogliptin (syr-322) in the US
10. Phyhealth Submits HMO Applications with Required Federal and State Agencies
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but is ... auto glass for most makes and models, in Grand Prairie, TX, located in the center ... have been a family owned business for the past 40 years with 32 convenient locations ...
(Date:8/22/2017)... ... 2017 , ... “Covert Awakening”: Walid’s spiritual journey from Islamic ... Hale, a consultant for the Intelligence Community. For more than ten years, ... East region. Julianne has written hundreds of reports for the US government ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Call Of Spiritual Duty”: a revelation in an ... author, C.S. Lizarde. Growing up on the streets of North Visalia, California, Carlos ... to apply the Biblical keys to his life, he noticed immediately that opportunities and ...
(Date:8/21/2017)... ... August 22, 2017 , ... The National Association of ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting more than 850,000 members, a thriving eChapter ...
(Date:8/21/2017)... ... , ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired ... will be able to vote for their favorite Chef among the following: , GREECE, ... Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Law and Gulf Coast Regional Blood Center to host a ... Mostyn Law family has had 3 members that needed blood ... Law is partnering with Gulf Coast Regional Blood Center of ... Blood supplies are running low. Gulf Coast Regional Blood Center,s inventory ... That is why the blood center reached out to Mostyn ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: